To compare radiation dosimetry of various cardiac structures and other thoracic tissue, such as lung fields and non-treated breast, associated with breast irradiation (left versus right-sided) in supine versus prone treatment positions.
Material and Methods:
Twenty-four post-lumpectomy patients (8 left-sided, 16 right-sided) underwent non-contrast 2mm slice thickness radiotherapy (RT) planning CT scans in the supine and prone positions. Optimized tangential breast RT plans were generated. In all cases, prescribed RT dose was 50Gy in 2Gy daily fractions. Twenty specific structures (whole heart, atria and ventricles, major vessels, cardiac valves, epicardial coronary arteries including left anterior descending (LAD), ipsilateral/contralateral lung and nontreated breast) were contoured on each CT dataset based on a published reference atlas. Maximum, minimum, mean doses and volume (cm³) were compared for all structures in both supine and prone positions. Whole heart V5, V25 and V30 as well as lung V20 were evaluated. The independent twosample t-test was used to determine the impact of treatment laterality and the paired t-test for the treatment positioning on RT dosimetry respectively, with p<0.05 considered significant.
Results: Left compared to right-sided breast irradiation significantly increased maximum (p<0.001) and mean (p<0.001) whole heart dose, as well as doses to individual cardiac structures, in both prone and supine positions. Prone versus supine positioning significantly increased maximum whole heart dose 25.8Gy versus 19.2Gy (p=0.007) and mean LAD artery 8.4Gy vs. 5.0Gy respectively (p=0.03). Whole heart V5 (3.9 vs. 2.5%), V25 (1.4 vs. 0.8%), and V30 (1.1 vs. 0.7%), did not differ significantly between prone and supine positions. Table 1 illustrates comparisons of other individual cardiac structures. As anticipated, maximum dose (48.5 vs. 50.3Gy), mean dose (3.3 vs. 6.5Gy) and V20 (5.3% vs. 11.5%) to the ipsilateral lung (p<0.001 for all comparisons) were reduced when patients were treated in the prone versus supine position.
Conclusion:
A statistically higher radiation dose was seen to the whole heart and various cardiac structures, including atria, ventricles and LAD artery, for left compared to rightsided breast cancer patients. Furthermore, prone positioning increased maximum whole heart and LAD artery doses, despite its known benefit in reducing dose-volume effects to lung tissue. This is one of few studies to assess differential radiation doses to individual cardiac structures. , inflammation [interleukin-6 (IL-6), IL-8, and C-reactive protein (CRP)], and tumor load [carcinoembryonic antigen (CEA), and cytokeratin fragment 21-1 (Cyfra 21-1)] was developed and validated. Finally, the model was extended with alpha-2-macroglobulin (α2M), serum interleukin-2 receptor (sIL2r), toll-like receptor 4 (TLR4), and vascular endothelial growth factor (VEGF).
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Material and Methods:
The model was developed and validated on respectively 182 and 181 inoperable stage I-IIIB NSCLC patients treated radically with (chemo)radiotherapy. It included the mentioned clinical features, and bloodbiomarkers were selected by least absolute shrinkage and selection operator (LASSO). Discrimination was reported by means of internal 10-fold cross-validated (CV) and external concordance index (c-index).
Results:
The inclusion of OPN and Cyfra 21-1 (hazard ratios of 3.3 and 1.7) in this clinical model significantly increased the c-index from 0.66 to 0.70 (10-fold CV=0.64 and 0.67; c-index external = 0.62 and 0.66). The calibration slope of the prognostic index in the validation cohort was 0.66 (p<0.01), therefore requiring re-calibration. Further extension of the model by selecting from the 4 additional blood biomarkers yielded a c-index of 0.67 (10-fold CV = 0.66), TLR4 was left unincluded, and resulted in a better fitting model (likelihood ratio test: p=0.01; Table 1 ). Hypoxia is known to be present in NSCLC adversely affecting disease progression and response to radiation treatment. Likewise, tumor load is often associated with disease development and prognosis. The value of hypoxia and tumor load associated markers OPN and Cyfra 21-1, was confirmed in this study. Extension of the model included α2M, sIL2r, and VEGF, with higher concentrations of these new markers being associated with a worse prognosis. α2M, a previously identified candidate predictor for radiation pneumonitis was found to be a prognostic factor in NSCLC. IL-2 was already identified as an independent prognostic marker in patients with advanced NSCLC. The correlation of IL-2 with shorter survival was confirmed in these cohorts and may be of relevance for patients receiving IL-2 immunotherapy. Finally, VEGF, the angiogenesis factor found in a variety of solid tumors including NSCLC, was found to be of added value in the extended model.
________________________________________________________________________________
Conclusion:
In conclusion, we improved and validated a clinical model with inclusion of hypoxia and tumor-load related blood-biomarkers. New immunological markers were associated with overall survival. Currently we are aiming to extend these models to include imaging information (Radiomics). Purpose or Objective: Intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) are widely used in the treatment of advanced stage non-small cell lung cancer (NSCLC). These techniques deliver conformal dose distributions at the cost of increased target dose heterogeneity (particularly IMRT) and larger volumes of surrounding healthy tissues receiving low doses (particularly VMAT). We evaluated whether these dosimetric differences between IMRT and VMAT are of influence on treatment toxicity and outcome.
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Material and Methods:
We retrospectively assessed a cohort of 189 consecutive patients with stage III NSCLC having undergone radical (chemo-)radiotherapy using IMRT (until 2011 (until ) or VMAT (starting in 2011 . Most patients (n= 182) received 66 Gy in 33 (once-daily) fractions to the primary tumour and involved hilar/mediastinal lymph nodes based on FDG-PET/CT. Concurrent chemoradiation (CCR; n = 122) consisted of 2 courses of etoposide cisplatinum, whereas sequential treatment (n = 56) consisted of 3 courses of gemcitabine cisplatinum. Acute and late toxicity were assessed using the RTOG radiation morbidity scoring criteria for esophageal and pulmonary toxicity. Follow-up visits were planned every 3 months (first 2 years), biannually thereafter. Median overall survival (OS) was calculated using Kaplan-Meyer survival analysis. Differences between the groups receiving IMRT and VMAT were statistically tested using the Mann-Whitney-U or Chi-square test, where appropriate.
Results: Gender, age, performance score, clinical (tumour and nodal) stage and radiation dose did not significantly differ between the IMRT (n= 93) and VMAT (n= 96) groups. Patients undergoing IMRT, however, received less concurrent chemotherapy compared to patients treated with VMAT (n=51 vs n=71; p= 0.007). Incidences of grade ≥2 and ≥3 acute esophageal toxicity (AET) were significantly lower for IMRT compared to VMAT (28 vs 57 patients, p<0.001; and 6 vs 17 patients, p= 0.025, respectively). Maximum grade acute and late pulmonary toxicity did not differ between groups (p=0.57 and p= 0.14, respectively). Grade ≥3 late esophageal toxicity was scored in 1 and 3 patients after IMRT and VMAT, respectively. Median follow-up for the patients alive was 32 months (range 2.4-82.1 months). Median OS was 23.9 months (95% CI 19.6-28.1), without a significant difference between the groups (23.9 and 24.9 months for IMRT and VMAT, respectively; p=0.70).
